AbCellera Investor Conference Presentation Deck
JPM HEALTHCARE CONFERENCE 2024
COPYRIGHT © ABCELLERA
13
SUMMARY
Continued focus
on high-value
programs
and strategic
partnerships.
With our differentiated technology
position and $1B+ in liquidity, we have a
long cash runway for focused strategic
investment and execution.
Completion of Engine
Over the next 2 years we will continue to invest in the
final stage of our engine, including construction and
commissioning of our manufacturing facility.
Our Portfolio of Partnered Programs
In 2024, we anticipate partnership deals from our
T-cell engager platform.
Our partnership strategy is to focus on select high
value strategic partnerships, not deal volume.
Our Portfolio of Internal Programs
We expect ABCL575 and ABCL635 to enter clinical
development in 2025.
In 2024n and 2025, we expect additional first-in-class
development candidates from our GPCR and ion
channel platform.View entire presentation